Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
We maintain our fair value estimate for TSMC stock.
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Trying to make sense of a share caught up in irrational exuberance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,156.70 | 21.00 | 0.23% |
| CAC 40 | 8,262.70 | 11.87 | -0.14% |
| DAX 40 | 24,154.47 | 87.77 | 0.36% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,589.99 | 30.41 | 0.29% |
| HKSE | 26,045.27 | 348.99 | -1.32% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 58,944.27 | 574.07 | -0.96% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,936.30 | 26.20 | 0.29% |
| SSE Composite Index | 4,044.29 | 11.26 | -0.28% |